De Ranieri Deirdre, Fenny Nana Sarkoah
Pediatr Ann. 2017 Jan 1;46(1):e8-e12. doi: 10.3928/19382359-20161213-03.
Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as a therapeutic agent has expanded over the past couple of decades as its anti-inflammatory and immune-modulatory mechanisms of action have been elucidated. It is now used "off-label" to treat other autoimmune diseases. This article focuses on the role of IVIG in the treatment of PIDDs characterized by absent or deficient antibody production. Replacement doses are given on a monthly basis in these conditions as a prophylactic measure to prevent acute and serious bacterial infections. [Pediatr Ann. 2017;46(1):e8-e12.].
静脉注射免疫球蛋白（IVIG）作为原发性免疫缺陷病（PIDD）的抗体替代疗法已应用超过50年。在过去几十年中，随着其抗炎和免疫调节作用机制的阐明，其作为治疗剂的作用不断扩展。目前它被“超适应证”用于治疗其他自身免疫性疾病。本文重点关注IVIG在治疗以抗体产生缺乏或不足为特征的PIDD中的作用。在这些情况下，每月给予替代剂量作为预防措施，以防止急性和严重细菌感染。[《儿科年鉴》。2017年；46(1):e8 - e12。]
